缩写名/全名 |
EXPERT REV CLIN PHAR
Expert Review of Clinical Pharmacology |
||||||||||||||||||||
ISSN号 | 1751-2433 | ||||||||||||||||||||
研究方向 | PHARMACOLOGY & PHARMACY- | ||||||||||||||||||||
影响因子 | 2015:2.488, 2016:2.932, 2017:2.758, 2018:2.776, 2019:3.481, | ||||||||||||||||||||
出版国家 | ENGLAND | ||||||||||||||||||||
出版周期 | |||||||||||||||||||||
年文章数 | 83 | ||||||||||||||||||||
出版年份 | 0 | ||||||||||||||||||||
是否OA | No | ||||||||||||||||||||
审稿周期(仅供参考) | |||||||||||||||||||||
录用比例 | |||||||||||||||||||||
投稿链接 | https://mc.manuscriptcentral.com/erf | ||||||||||||||||||||
投稿官网 | http://www.tandfonline.com/toc/ierj20/current | ||||||||||||||||||||
h-index | 32 | ||||||||||||||||||||
CiteScore |
|
||||||||||||||||||||
PubMed Central (PMC)链接 | http://www.ncbi.nlm.nih.gov/nlmcatalog?term=1751-2433%5BISSN%5D | ||||||||||||||||||||
中科院SCI期刊分区 ( 2018年新版本) |
|
||||||||||||||||||||
中科院SCI期刊分区 ( 2020年新版本) |
|
中国学者近期发表的论文 | |
1. | Novel developments of hepatitis B: treatment goals, agents and monitoring tools. Author: Mak LY1, Seto WK1,2,3, Fung J1,3, Yuen MF1,3. Journal: Expert Rev Clin Pharmacol. 2019 Feb;12(2):109-120. doi: 10.1080/17512433.2019.1567327. Epub 2019 Jan 21. PubMed DOI |
2. | Patisiran for the treatment of hereditary transthyretin-mediated amyloidosis. Author: Yang J1. Journal: Expert Rev Clin Pharmacol. 2019 Feb;12(2):95-99. doi: 10.1080/17512433.2019.1567326. Epub 2019 Jan 18. PubMed DOI |
3. | A meta-analysis of naldemedine for the treatment of opioid-induced constipation. Author: Song X1, Wang D1, Qu X2, Dong N1, Teng S1. Journal: Expert Rev Clin Pharmacol. 2019 Feb;12(2):121-128. doi: 10.1080/17512433.2019.1570845. Epub 2019 Jan 24. PubMed DOI |
4. | Lorlatinib for the treatment of anaplastic lymphoma kinase-positive non-small cell lung cancer. Author: Yang J1, Gong W1. Journal: Expert Rev Clin Pharmacol. 2019 Mar;12(3):173-178. doi: 10.1080/17512433.2019.1570846. Epub 2019 Jan 30. PubMed DOI |
5. | Time course of arsenic species in red blood cells of acute promyelocytic leukemia (APL) patients treated with single agent arsenic trioxide. Author: Guo M1, Wang B1, Liu S2,3, Wang W1, Gao C1, Hu S1, Fan S2,3, Hai X1, Zhou J2,3. Journal: Expert Rev Clin Pharmacol. 2019 Apr;12(4):371-378. doi: 10.1080/17512433.2019.1586532. Epub 2019 Mar 11. PubMed DOI |
6. | Revefenacin for the treatment of chronic obstructive pulmonary disease. Author: Li F1, Yang J2. Journal: Expert Rev Clin Pharmacol. 2019 Apr;12(4):293-298. doi: 10.1080/17512433.2019.1587292. Epub 2019 Mar 22. PubMed DOI |
7. | JAK3-selective inhibitor peficitinib for the treatment of rheumatoid arthritis. Author: Qiu Q1, Feng Q1, Tan X2, Guo M3. Journal: Expert Rev Clin Pharmacol. 2019 Jun;12(6):547-554. doi: 10.1080/17512433.2019.1615443. Epub 2019 May 13. PubMed DOI |
8. | A comprehensive review of the clinical utility of and a combined analysis of the clozapine/norclozapine ratio in therapeutic drug monitoring for adult patients. Author: Schoretsanitis G1,2,3, Kane JM1, Ruan CJ4, Spina E5, Hiemke C6, de Leon J7,8,9. Journal: Expert Rev Clin Pharmacol. 2019 May 10. doi: 10.1080/17512433.2019.1617695. [Epub ahead of print] PubMed DOI |
9. | Effect of rilpivirine on the pharmacokinetics of methadone in HIV-Infected Chinese patients. Author: Lei S1, Hong L1, Yang C1, Zhang S2, Zhang Y1, Huang S1, Xie R1, Li X1, Ma Q3, Li H1. Journal: Expert Rev Clin Pharmacol. 2019 Jun;12(6):565-571. doi: 10.1080/17512433.2019.1608523. Epub 2019 May 15. PubMed DOI |
10. | Safety and efficacy of targeted agents monotherapy in advanced NSCLC. Author: Zhang Q, Wu YL. Journal: Expert Rev Clin Pharmacol. 2016;9(1):143-55. doi: 10.1586/17512433.2016.1101340. Epub 2015 Nov 11. Review. PubMed |
|
|